Contact Us
Drug Search Results
More Filters [+]

Volixibat

Alternative Names: volixibat, shp-626, shp626, shp 626
Latest Update: 2024-12-10
Latest Update Note: News Article

Product Description

Mechanisms of Action: IBAT Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Breakthrough Therapy - Biliary Cirrhosis|Cholangitis|Pruritus *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Mirum Pharmaceuticals
Company Location: FOSTER CITY CA 94404
Company CEO: Christopher Peetz
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Volixibat

Countries in Clinic: Argentina, Belgium, Brazil, Canada, China, France, Germany, Israel, Italy, Netherlands, Spain, Switzerland, United Kingdom, United States

Active Clinical Trial Count: 7

Highest Development Phases

Phase 2: Biliary Cirrhosis|Cholangitis|Cholangitis, Sclerosing|Liver Cirrhosis|Pruritus

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
jRCT2041240104

P2

Recruiting

Pruritus|Cholangitis|Biliary Cirrhosis

2027-12-01

VLX-601

P2

Unknown Status

Biliary Cirrhosis|Pruritus|Cholangitis

2027-10-23

VANTAGE

P2

Active, not recruiting

Biliary Cirrhosis|Cholangitis|Pruritus

2027-04-19

VISTAS

P2

Active, not recruiting

Pruritus|Cholangitis, Sclerosing

2026-11-17

Recent News Events

Date

Type

Title

12/10/2024

News Article

 Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11/14/2024

News Article

 Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting

11/12/2024

News Article

 Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

11/08/2024

News Article

 Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08/01/2020

PubMed

 Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.

05/01/2020

PubMed

 [The inhibitors of the apical sodium-dependent bile acid transporter (ASBT) as promising drugs].

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions